Table 2.
Characteristics according to pathologic reports in patients with gray zone PSA levels
| Non-CSPCa | CSPCa | P value | |
|---|---|---|---|
| Mean age (SD), y | 63.23 (6.71) | 65.14 (5.87) | 0.204 |
| Median PSA (IQR), ng/ml | 6.29 (5.24–7.95) | 7.61 (5.34–9.21) | 0.206 |
| Median PV (IQR), ml | 49.66 (32.90-68.05) | 31.40 (21.69–37.32) | < 0.001* |
| Median PSAD (IQR), ng/ml 2 | 0.13 (0.09–0.17) | 0.21 (0.17–0.29) | < 0.001* |
| Median FPSA/TPSA (IQR) | 0.16 (0.13–0.22) | 0.12 (0.09–0.15) | 0.001* |
| MRI results | 0.005* | ||
| PI-RADS 1–2 | 23 (44.2%) | 4 (13.8%) | |
| PI-RADS 3–5 | 29 (55.8%) | 25 (86.21%) | |
| 68 Ga-PSMA PET/CT results | < 0.001* | ||
| Negative | 40 (76.92%) | 2 (6.90%) | |
| Positive | 12 (23.08%) | 27 (93.10%) | |
| SUVmax | 3.75 (3.20–6.20) | 8.20 (6.50–12.70) | < 0.001* |
CSPCa, clinically significant prostate cancer; SD, standard deviation; PSA, prostate-specific antigen; IQR, interquartile range; PV, prostate volume; PSAD, prostate-specific antigen density; TPSA, total prostate-specific antigen; FPSA, free prostate-specific antigen; MRI, magnetic resonance imaging; PI-RADS, Prostate Imaging-Reporting and Data System; 68Ga-PSMA PET/CT, 68Ga-labeled prostate-specific membrane antigen positron emission tomography/computed tomography; SUVmax, maximum standardized uptake values
* p < 0.05